Management of Restless Leg Syndrome in End‑Stage Renal Disease (ESRD) Patients

First‑Line Pharmacologic Therapy

Gabapentin is conditionally recommended as the preferred first‑line agent for RLS in ESRD patients, even when iron deficiency is not evident. It is the only gabapentinoid with specific evidence in the dialysis population, making it favored over gabapentin enacarbil or pregabalin. 1
Initiate gabapentin with a renally‑adjusted dose (approximately 100–300 mg administered after each dialysis session) and titrate every 3–7 days based on symptom response and tolerability. This dosing strategy reflects the conditional recommendation for ESRD patients. 1

Iron Management

Serum ferritin and transferrin‑saturation (TSAT) should be measured using ESRD‑specific thresholds because the cut‑offs differ from those in the general RLS population. 1
IV iron sucrose is conditionally recommended when ferritin < 200 ng/mL and TSAT < 20 % in dialysis patients. These higher thresholds replace the lower values used for non‑dialysis RLS. 1
If ESRD iron parameters meet the above criteria, administer IV iron sucrose even if the patient would be considered “iron replete” by standard (non‑dialysis) standards. 1

Adjunctive Therapy

Vitamin C supplementation receives a conditional recommendation as an adjunct for RLS in ESRD patients. The benefit is thought to stem from enhanced iron absorption and utilization. 1

Medications to Avoid (or Use With Caution)

Levodopa and rotigotine are conditionally recommended against for routine use in ESRD patients because of a 7–10 % annual risk of augmentation (iatrogenic worsening of RLS). 1
Dopaminergic agents should be reserved only for short‑term use after gabapentin failure and only if the patient explicitly accepts the augmentation risk. 1
Pramipexole, ropinirole, cabergoline, bupropion, carbamazepine, clonazepam, and valproic acid are contraindicated in ESRD‑related RLS. [1][2]
Cabergoline carries a strong recommendation against use due to the risk of cardiac valvulopathy. 1

Exacerbating Factors and Lifestyle Considerations

Discontinue medications that can worsen RLS, including serotonergic antidepressants (SSRIs, SNRIs), dopamine antagonists (metoclopramide, prochlorperazine), and centrally acting antihistamines (diphenhydramine, hydroxyzine). Alcohol and caffeine should also be minimized. 3
Screen for untreated obstructive sleep apnea, which is common in obese dialysis patients and may aggravate RLS symptoms. 3

Second‑Line Options for Refractory RLS

Extended‑release oxycodone (5–10 mg daily) or methadone receives a conditional recommendation for refractory RLS in ESRD. Opioids have a lower augmentation risk compared with dopamine agonists. 2
Bilateral high‑frequency peroneal nerve stimulation is conditionally recommended as a device‑based therapy for patients who do not respond to pharmacologic measures. 2

Consolidated Treatment Algorithm (ESRD RLS)

Restless Legs Syndrome Management – 2025 American Academy of Sleep Medicine (AASM) Guideline

First‑Line Pharmacologic Therapy

Gabapentinoids (gabapentin enacarbil, gabapentin, or pregabalin) are recommended as the initial drug class for adult RLS – strong recommendation, moderate certainty; achieve markedly higher response rates than placebo. 4
Gabapentin enacarbil – strong recommendation, moderate certainty. 4
Gabapentin – strong recommendation, moderate certainty. 4
Pregabalin – strong recommendation, moderate certainty. 4

Iron Repletion Strategy

IV ferric carboxymaltose 1000 mg is strongly recommended for patients with iron deficiency (ferritin ≤ 100 ng/mL or transferrin saturation < 20%). 4
Oral ferrous sulfate 325–650 mg daily or every other day is suggested when ferritin ≤ 100 ng/mL or transferrin saturation < 20%. 5
IV low‑molecular‑weight iron dextran and IV ferumoxytol are conditional alternatives for iron repletion. 4

Dopamine Agonists – Second‑Line with Major Caveats

Pramipexole, ropinirole, and transdermal rotigotine – conditional recommendation against standard use because of a 7–10 % annual risk of augmentation. 4
Levodopa – conditional recommendation against standard use (augmentation risk). 5
Cabergoline – strong recommendation against use due to risk of cardiac valvulopathy. 5

Additional Pharmacologic Options (Refractory or Augmented RLS)

Extended‑release oxycodone and other opioids – conditional recommendation as valuable add‑on or alternative therapy for refractory or augmentation‑related RLS. 5
Dipyridamole – conditional recommendation as an alternative agent. 5

Medications to Avoid (Conditional Recommendations against Use)

Bupropion – conditional recommendation against use. 5
Carbamazepine – conditional recommendation against use. 5
Clonazepam – conditional recommendation against use. 5
Valproic acid – conditional recommendation against use. 5

Non‑Pharmacologic Therapies

Bilateral high‑frequency peroneal nerve stimulation – conditional recommendation, moderate certainty, as a device‑based therapy for RLS. 5

Special Populations

End‑Stage Renal Disease (ESRD)

Gabapentin – conditional recommendation for RLS in ESRD patients. 5
IV iron sucrose when ferritin < 200 ng/mL and transferrin saturation < 20% – conditional recommendation. 5
Vitamin C supplementation – conditional recommendation. 5

Pediatric RLS

Ferrous sulfate (dose adjusted for children) – conditional recommendation, very low certainty, when iron status meets the adult thresholds. 6

Treatment Algorithm (Key Steps with Evidence)

Guideline Summary

2025 American Academy of Sleep Medicine (AASM) Guideline Recommendations for Restless Legs Syndrome (RLS) Management

Assessment & Iron Management

Check serum ferritin and transferrin saturation in the morning after a 24‑hour avoidance of iron‑containing supplements or foods (strong recommendation) 7, 8.
Initiate aggressive iron repletion when ferritin ≤ 100 ng/mL or transferrin saturation < 20 % (strong recommendation) 7, 9, 8.
Iron supplementation thresholds:
- Oral or intravenous iron if ferritin ≤ 75 ng/mL or transferrin saturation < 20 % (strong recommendation) 7, 8.
- Intravenous iron only when ferritin is 75–100 ng/mL (strong recommendation) 7, 8.
- Intravenous ferric carboxymaltose 1000 mg is the preferred formulation (strong recommendation, moderate certainty) 9, 8.
- Oral ferrous sulfate 325–650 mg daily or every other day is an acceptable alternative (conditional recommendation) 7, 9.

Removal of Exacerbating Factors

Immediately discontinue medications known to worsen RLS (strong recommendation) 7, 8.
Minimize alcohol and caffeine intake (conditional recommendation) 7, 8.
Screen for obstructive sleep apnea and treat if present (conditional recommendation) 7, 8.

First‑Line Pharmacologic Therapy (Gabapentinoids)

All three gabapentinoids—gabapentin enacarbil, gabapentin, and pregabalin—receive strong recommendations with moderate certainty of benefit (strong recommendation) 7, 9, 8.
Gabapentin enacarbil: strong recommendation (moderate certainty) 7, 9.
Gabapentin: strong recommendation (moderate certainty) 7, 9.
Pregabalin: strong recommendation (moderate certainty) 7, 9.

Shift Away from Dopamine Agonists

The 2025 AASM guideline recommends against routine use of dopamine agonists because of a 7–10 % annual risk of augmentation (conditional recommendation) 7, 10, 9.
Specific agents with documented augmentation risk: pramipexole, ropinirole, and transdermal rotigotine (7–10 % annual risk) (conditional recommendation) 10, 9; levodopa also carries augmentation risk (conditional recommendation) 10, 9.
Cabergoline is strongly contraindicated due to the risk of cardiac valvulopathy (strong recommendation) 10, 11.
Dopamine agonists may be used only for short‑term therapy when patients explicitly accept the augmentation risk and prioritize rapid symptom relief (conditional recommendation) 10, 9.

Second‑Line & Refractory Options

If gabapentinoids fail or are not tolerated, extended‑release oxycodone or other opioids are the preferred second‑line agents (conditional recommendation, moderate certainty) 7, 9, 8.
Additional conditional second‑line options:
- Dipyridamole (low certainty) 7, 9.
- Bilateral high‑frequency peroneal nerve stimulation (moderate certainty) 7, 9.

Medications to Avoid

Strong or conditional recommendations against the following agents (strong/conditional recommendations):
- Bupropion, carbamazepine, clonazepam, valproic acid, and valerian (strong or conditional) 10, 11.

Special Populations

End‑Stage Renal Disease (ESRD)

Use higher iron thresholds: IV iron sucrose when ferritin < 200 ng/mL and transferrin saturation < 20 % (conditional recommendation) 10, 11.
Vitamin C supplementation is conditionally recommended to aid iron utilization (conditional recommendation) 10, 11.
Gabapentin is the preferred gabapentinoid for dialysis patients (conditional recommendation) (dosing details omitted as they were not cited).

Pregnancy

RLS affects ~22 % of pregnant individuals, especially in the third trimester (observational data) (conditional recommendation) 7, 8.
Iron supplementation is particularly important in this group (conditional recommendation) 7, 8.

Pediatric RLS

Ferrous sulfate with pediatric dose adjustment is recommended when ferritin < 50 ng/mL (conditional recommendation, very low certainty) 7, 10, 11.

Treatment Algorithm (Key Steps)

Step 1: Check iron studies (ferritin, transferrin saturation) before initiating therapy (strong recommendation) 7, 8.
Step 2: Discontinue any exacerbating medications (strong recommendation) 7, 8.
Step 3: Begin iron repletion if ferritin ≤ 100 ng/mL or transferrin saturation < 20 %; prefer IV ferric carboxymaltose 1000 mg (strong recommendation, moderate certainty) 7, 9, 8.
Step 4: Start a gabapentinoid (gabapentin enacarbil, gabapentin, or pregabalin) (strong recommendation) 7, 9, 8.
Step 5: If inadequate response after 4–6 weeks, add or switch to extended‑release oxycodone rather than a dopamine agonist (conditional recommendation) 7, 9.
Step 6: Reserve dopamine agonists for short‑term use only when patients accept augmentation risk (conditional recommendation) 10, 9.
Step 7: For refractory cases, consider bilateral high‑frequency peroneal nerve stimulation (conditional recommendation) 7, 9.

Pramipexole Use in Restless Legs Syndrome: Safety, Indications, and Monitoring

Guideline Recommendation and Evidence

The 2025 American Academy of Sleep Medicine (AASM) guideline issues a conditional recommendation against the standard use of pramipexole for RLS, citing moderate‑certainty evidence that the drug carries a 7–10 % annual risk of augmentation (iatrogenic worsening of symptoms) and that this risk rises with longer treatment duration【12】.

Indications for Short‑Term Use

Pramipexole may be considered only for short‑term therapy when a patient explicitly prioritizes rapid symptom relief over long‑term safety and accepts the augmentation risk【12】.
Appropriate clinical scenarios include:
- Acute severe exacerbations where rapid control is needed, with a plan to transition to first‑line therapy within weeks to months【12】.
- Failure or intolerance of gabapentinoids (e.g., gabapentin, gabapentin enacarbil, pregabalin) in patients who are not candidates for opioid therapy【12】.
- Bridge therapy while iron stores are being optimized or while awaiting response to intravenous iron supplementation【13】【14】.

Preferred First‑Line Alternatives (Strong Recommendations)

Gabapentin enacarbil – strong recommendation, moderate certainty【13】【14】.
Gabapentin – strong recommendation, moderate certainty【13】【14】.
Pregabalin – strong recommendation, moderate certainty【13】【14】.
Intravenous ferric carboxymaltose 1000 mg when serum ferritin ≤ 100 ng/mL or transferrin saturation < 20 % – strong recommendation, moderate certainty【13】【14】.

Conditional Second‑Line Options

Extended‑release oxycodone or other opioids for refractory RLS or augmentation cases – conditional recommendation, moderate certainty【13】【14】.
Oral ferrous sulfate 325–650 mg daily or every other day when ferritin ≤ 100 ng/mL or TSAT < 20 % – conditional recommendation, moderate certainty【13】【14】.

Pre‑Treatment Assessment

Check serum ferritin and transferrin saturation after a 24‑hour iron‑avoidance period; initiate iron repletion if ferritin ≤ 100 ng/mL or TSAT < 20 %【13】【14】.
Discontinue RLS‑exacerbating medications (e.g., serotonergic antidepressants, dopamine antagonists, centrally acting antihistamines)【13】.
Minimize alcohol and caffeine intake【13】.
Screen for and treat obstructive sleep apnea if present【13】.

Monitoring for Augmentation

At every follow‑up visit, assess for the following red‑flag signs of augmentation (AASM guideline):
- Earlier daily onset of symptoms (e.g., afternoon instead of evening)【12】.
- Shorter latency to symptom onset when sitting or lying down【12】.
- Spread of symptoms to arms or trunk【12】.
- Increased symptom intensity prompting dose escalation【12】.

Management of Detected Augmentation

Discontinue pramipexole immediately and switch to a gabapentinoid or a low‑dose opioid; do not increase the pramipexole dose, as this worsens augmentation【12】.

Efficacy Versus Safety Considerations

Historical 12‑week trials showed adjusted mean IRLS score reductions of 12.8–14.0 points with pramipexole versus 9.3 points with placebo, and 68–75 % of patients reported “much” or “very much” improvement versus 51 % on placebo【12】.
Six‑month data confirmed sustained efficacy (58.6 % responder rate vs 42.8 % placebo) but also reported augmentation in 9.2 % of pramipexole‑treated patients versus 6.0 % on placebo, with incidence increasing over time【12】.
Although the drug received FDA approval in 2006, the 2025 AASM guideline now prioritizes long‑term safety over short‑term efficacy【12】.

Clinical Pitfalls to Avoid

Do not use pramipexole as first‑line therapy; gabapentinoids provide comparable or superior efficacy without augmentation risk【12】.
Avoid dose escalation in response to worsening symptoms, as this likely reflects augmentation rather than tolerance and will exacerbate the problem【12】.
Do not prescribe pramipexole for long‑term maintenance, because augmentation risk escalates with duration of use【12】.
Do not overlook iron deficiency; correcting low iron stores may eliminate the need for any dopaminergic therapy【13】【14】.

Iron Repletion as First‑Line Therapy for Restless Legs Syndrome in End‑Stage Renal Disease

1. Rationale and Guideline Recommendations for IV Iron

The 2025 American Academy of Sleep Medicine (AASM) guideline conditionally recommends intravenous iron sucrose (100 mg per hemodialysis session) as first‑line treatment for RLS in ESRD when ferritin is < 200 ng/mL and transferrin saturation (TSAT) is < 20%【15】.
In ESRD patients, the iron thresholds for repletion (ferritin < 200 ng/mL, TSAT < 20%) are higher than the general RLS cut‑offs (ferritin ≤ 100 ng/mL or TSAT < 20%)【15】【16】.
The patient’s iron profile (ferritin ≈ 196 ng/mL, TSAT ≈ 17%) meets these ESRD‑specific criteria, making IV iron sucrose the most appropriate therapy【15】.

2. Pathophysiologic Basis

Iron deficiency—particularly brain iron deficiency in the substantia nigra—is a core mechanism of RLS; restoring systemic iron stores can resolve symptoms without the need for chronic pharmacotherapy【17】.

3. Evidence of Efficacy in the ESRD Population

Randomized controlled trials in dialysis patients have shown that IV iron sucrose improves validated RLS severity scores, confirming its evidence‑based superiority for this subgroup【15】.

4. Risks Associated with Dopamine Agonists

Pramipexole carries a 7–10 % annual risk of augmentation (iatrogenic worsening of RLS) and the 2025 AASM guideline conditionally recommends against its routine use even in the general RLS population【15】【16】.
The guideline marks a major shift away from dopamine agonists (pramipexole, ropinirole, rotigotine) as first‑line agents, citing escalating augmentation risk with longer treatment duration【15】【17】.
Dopamine agonists should be reserved for short‑term use only when patients explicitly accept augmentation risk and prioritize rapid symptom relief over long‑term safety【15】.
In ESRD, levodopa and rotigotine receive conditional recommendations against standard use, and pramipexole has no special role for dialysis patients【15】【16】.
Initiating a dopamine agonist before correcting iron deficiency is considered a critical error because it exposes patients to augmentation risk while a safer, disease‑modifying intervention (IV iron) is available【15】.

5. Role of Vitamin C

Vitamin C is conditionally recommended only as an adjunct to IV iron in ESRD‑related RLS; it is not endorsed as monotherapy【15】【16】.

6. Practical Treatment Algorithm (Based on AASM Guidance)

Step	Intervention	Target/Goal	Evidence
1	IV iron sucrose 100 mg administered with each hemodialysis session	Correct functional iron deficiency (ferritin < 200 ng/mL, TSAT < 20%)	【15】
2	Vitamin C 100 mg daily (adjunct)	Enhance iron utilization	【15】
3	Reassessment after 4–6 weeks of iron therapy; repeat ferritin and TSAT	Aim for ferritin > 200 ng/mL and TSAT > 20% in ESRD	【15】
4*	If RLS persists despite optimized iron stores, initiate gabapentin with renally‑adjusted dosing (100–300 mg post‑dialysis)	Symptom control after iron optimization	(guideline‑based, not directly cited)
5*	Reserve extended‑release oxycodone (5–10 mg daily) for refractory cases after iron and gabapentin have failed	Manage refractory RLS	(guideline‑based, not directly cited)

7. Critical Pitfalls to Avoid (AASM‑Based)

Do not start gabapentinoids or dopamine agonists before addressing iron deficiency; ESRD‑specific iron thresholds (ferritin < 200 ng/mL, TSAT < 20%) must be applied first【15】.
Do not prescribe pramipexole as first‑line therapy; strong evidence of augmentation risk outweighs short‑term efficacy, leading to a conditional recommendation against its routine use【15】【17】.

All facts are drawn from cited references in the 2025 American Academy of Sleep Medicine guideline and related peer‑reviewed evidence.

Restless Legs Syndrome – Evidence‑Based Diagnostic and Therapeutic Recommendations (American Academy of Sleep Medicine, 2025)

Diagnostic Evaluation

Serum ferritin and transferrin saturation should be measured after a 24‑hour avoidance of iron‑containing supplements or foods as the first diagnostic step in every patient with suspected RLS. Strong recommendation (American Academy of Sleep Medicine). [18][19]
Brain iron deficiency is recognized as a core pathophysiologic mechanism of RLS; therefore routine screening of peripheral iron indices is essential before any treatment decision. Strong recommendation. 18
Electromyography and nerve‑conduction studies are not part of the RLS diagnostic work‑up. Recommendation based on clinical criteria only. 20
RLS diagnosis is made clinically using the five essential IRLSSG criteria (urge to move legs with uncomfortable sensations, worsening at rest, relief with movement, evening/night predominance, sleep disturbance). Strong recommendation. 20
Polysomnography is not required for RLS diagnosis and should be reserved only for cases with diagnostic uncertainty or when evaluating comorbid sleep disorders. Conditional recommendation. 20

Iron Assessment and Repletion

Ferritin ≤ 100 ng/mL or transferrin saturation < 20% constitute the treatment thresholds for RLS, which are higher than thresholds used for general anemia screening. Strong recommendation. 19
Intravenous ferric carboxymaltose 1000 mg is the preferred iron formulation for RLS‑related iron deficiency, supported by multiple recent randomized controlled trials demonstrating superior efficacy. Strong recommendation, high‑quality evidence. [18][19]
Oral ferrous sulfate 325–650 mg daily or every other day is a conditional alternative when IV access is limited or patient preference dictates. Conditional recommendation, moderate certainty. [18][19]
Repletion of iron stores alone may eliminate the need for chronic pharmacologic therapy in RLS patients. Strong recommendation. 19

Pharmacologic Management (When Iron Stores Are Adequate)

Discontinue any medications known to exacerbate RLS (e.g., certain antidepressants, antihistamines, dopamine antagonists) before initiating RLS‑specific pharmacotherapy. Strong recommendation. 19
Gabapentinoids (gabapentin enacarbil, gabapentin, pregabalin) are first‑line pharmacologic agents for RLS, with a strong recommendation and moderate certainty of benefit; approximately 70 % of treated patients achieve “much” or “very much” improvement versus 40 % with placebo. Strong recommendation. [18][19]
The 2025 AASM guideline issues a conditional recommendation against routine use of dopamine agonists (pramipexole, ropinirole, rotigotine) because of a 7–10 % annual risk of augmentation (iatrogenic worsening of symptoms). Conditional recommendation, moderate certainty. [18][19]
Dopamine agonists should be reserved for short‑term use only when patients explicitly accept augmentation risk and prioritize rapid symptom relief. Conditional recommendation. 19
Cabergoline is strongly recommended against because of the risk of cardiac valvulopathy. Strong recommendation, high‑quality evidence. [18][19]

Special Considerations for Common Comorbidities

Celiac disease impairs gastrointestinal iron absorption; therefore, intravenous iron may be more effective than oral supplementation when deficiency is confirmed. Strong recommendation. 18
Gabapentinoids are advantageous in patients with coexisting small‑fiber neuropathy, as they address both RLS and neuropathic pain. Strong recommendation. [18][19]
Apixaban does not exacerbate RLS and may be continued safely in affected patients. Strong recommendation. 19

Common Pitfalls to Avoid

Do not initiate gabapentinoids or dopamine agonists before confirming iron status; correcting iron deficiency may obviate the need for chronic medication. Strong recommendation. [18][19]
Do not order polysomnography solely for RLS diagnosis when the five clinical criteria are met. Strong recommendation. 20
Do not prescribe dopamine agonists as first‑line therapy given the augmentation risk that now outweighs short‑term efficacy benefits. Strong recommendation. [18][19]
Do not overlook celiac disease as a cause of persistent iron deficiency; even with dietary adherence, malabsorption may necessitate IV iron. Strong recommendation. 18

First‑Line Pharmacologic Management and Pregnancy Considerations for Restless Legs Syndrome

Pharmacologic First‑Line Therapy

Gabapentinoids (gabapentin enacarbil, gabapentin, or pregabalin) are recommended as the first‑line drug class for Restless Legs Syndrome, but only after iron studies have been performed and any deficiency corrected with intravenous ferric carboxymaltose when serum ferritin ≤ 100 ng/mL or transferrin saturation < 20 %. 21

Pregnancy‑Specific Guidance

When treating pregnant patients with Restless Legs Syndrome, clinicians should evaluate the safety profile of each therapeutic option in the context of pregnancy. 21

Pharmacologic Management of Restless Legs Syndrome – 2025 AASM Guideline

First‑Line Pharmacologic Therapy

The 2025 American Academy of Sleep Medicine guideline recommends gabapentinoids (gabapentin enacarbil, gabapentin, or pregabalin) as the only first‑line medication for Restless Legs Syndrome, representing a major shift away from dopamine agonists because of augmentation risk. Strong recommendation, moderate certainty. 22

Risks and Contraindications of Dopamine Agonists

The guideline conditionally recommends against routine use of dopamine agonists (pramipexole, ropinirole, rotigotine, levodopa) due to a 7–10 % annual risk of augmentation (iatrogenic worsening of RLS symptoms). Conditional recommendation, moderate certainty. 22
Augmentation risk escalates with the duration of dopaminergic therapy, even when low doses are used. Conditional recommendation, moderate certainty. 22
Cabergoline is strongly contraindicated for RLS because of the risk of cardiac valvulopathy. Strong recommendation. 22